Pre-filled Syringes San Francisco Conference 2020

SMi Group 14 - 15 September 2020, San Francisco, USA.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

As part of SMi's leading Injectable conference series, we will assess digital health and connected devices, biologics, biosimilars and biocompatibility for drug device combination products, platform and device selection, regulatory insights and explore the West Coast's biotech innovators. This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

Plus, a workshop on human factors and risk management:

  • Integration of Human Factors Engineering processes in risk management saves time and money in product development
  • Effective identification of use-related risk helps inform constructive design decisions
  • Mitigation of use-related risk improves treatment outcomes for end users
  • Understanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization

Benefits of attending

  • EXPLORE the latest industry case studies in platform approaches and connected devices
  • GAIN insights from leading industry and regulatory experts on the pre-filled syringes environment
  • HEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space
  • ENGAGE in the key challenges and topics of the field in two interactive half-day workshops

Chairs for 2020

  • Shannon Clark, Principal, UserWise
  • Steven Badelt, Founder and Managing Partner, Suttons Creek, Inc.

Featured 2020 speakers include

  • Kristina Lauritsen, Combination Products Regulatory Advisor, FDA/CDER
  • Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI
  • Christine Lynn Lanning, Distinguished Scientist, Device Area Leader, Safety Assessment/Merck & Co., Inc
  • Khaudeja Bano, Senior Medical Director, Abbott Laboratories
  • Jace Blackburn, Smart Device Engineer, Genentech
  • Michael Koby, Senior Principle Scientist, Pfi zer
  • James Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
  • Walter Goodwin, Device Engineer, Device Development & Clinical Packaging Engineering, Gilead Sciences
  • Katie Atkinson, Manager Human Factors Engineering, Bigfoot Biomedical

Early-bird rates

  • Book by 29th May and save £300
  • Book by 30th June and save £200

For further information and to register, please visit:
http://www.prefilled-sanfrancisco.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...